Adults as young as 50 may now qualify for an RSV vaccine if they have certain health conditions, according to a quiet update ...

In a new consensus statement, the European Society of Cardiology has declared vaccinations for common infections to be a ...

RSV vaccine access expanded to some people in their 50s, according to CDC website The Trump administration appears to be expanding RSV vaccinations to some adults starting at age 50 instead of 60 ...

Moderna's RSV vaccine gets expanded approval for 18-59 year olds at high risk of severe illness, marking a significant step in vaccine protection.

The U.S. Food and Drug Administration expanded its approval of Moderna's respiratory syncytial virus (RSV) vaccine on Thursday to include adults under the age of 60 at increased risk of the disease.

June 26 (UPI) -- Merck's Enflonsia vaccine for respiratory syncytial virus won approval from the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices.

The Food and Drug Administration (FDA) has expanded the approval of mResvia (respiratory syncytial virus [RSV] vaccine) to include active immunization in individuals 18 through 59 years of age who ...

Expanded Approval: Moderna’s mRESVIA vaccine is now FDA-approved for adults aged 18–59 years with an increased risk for respiratory syncytial virus (RSV)-related lower respiratory tract disease.

Moderna's RSV vaccine gets expanded approval for 18-59 year olds at high risk of severe illness, marking a significant step in vaccine protection.

Moderna's RSV vaccine gets expanded approval for 18-59 year olds at high risk of severe illness, marking a significant step in vaccine protection.

U.S. vaccine advisers will discuss recommendations for flu vaccines containing the preservative thimerosal and a combination measles shot for children this month, putting topics of concern to ...